{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:09:43Z","timestamp":1776920983334,"version":"3.51.2"},"reference-count":36,"publisher":"American Chemical Society (ACS)","issue":"4","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP160102906"],"award-info":[{"award-number":["DP160102906"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1160404"],"award-info":[{"award-number":["OPP1160404"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2023,4,3]]},"DOI":"10.1021\/acs.molpharmaceut.3c00072","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T06:44:05Z","timestamp":1678862645000},"page":"2256-2265","source":"Crossref","is-referenced-by-count":7,"title":["Implications of the Digestion of Milk-Based Formulations for the Solubilization of Lopinavir\/Ritonavir in a Combination Therapy"],"prefix":"10.1021","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1773-5401","authenticated-orcid":true,"given":"Malinda","family":"Salim","sequence":"first","affiliation":[{"name":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2037-853X","authenticated-orcid":true,"given":"Andrew J.","family":"Clulow","sequence":"additional","affiliation":[{"name":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia"},{"name":"Australian Synchrotron, ANSTO, 800 Blackburn Road, Clayton, Victoria 3168, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Hawley","sequence":"additional","affiliation":[{"name":"Australian Synchrotron, ANSTO, 800 Blackburn Road, Clayton, Victoria 3168, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-590X","authenticated-orcid":true,"given":"Ben J.","family":"Boyd","sequence":"additional","affiliation":[{"name":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia"},{"name":"Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen 2100, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"316","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"ref1\/cit1","unstructured":"Use of Liquids and\/or Soft Foods as Vehicles for Drug Administration:\nGeneral Considerations for Selection and In Vitro Methods for Product\nQuality Assessments; U.S. Food and Drug Administration, 2018. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-liquids-andor-soft-foods-vehicles-drug-administration-general-considerations-selection-and-vitro (accessed 2020-08-06)."},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114139"},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2010.01.038"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600750716"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.5530\/jyp.2016.2.3"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.01.022"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-021-03085-x"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.10.027"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00541"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b01333"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b00276"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00320-5"},{"key":"ref13\/cit13","unstructured":"A Dose-Escalation Study to Investigate Safety\nand Toleration of OZ439. U.S. National\nInstitutes of Health, 2012. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01713608 (accessed 2020-08-06)."},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.0c00475"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.12.3218"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.7.2484"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000014"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f2be1d"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02455.x"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.044677"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-016-0649-1"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0437744100"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011052932607"},{"key":"ref24\/cit24","doi-asserted-by":"crossref","unstructured":"Reddy, B. P.; Reddy, K. R.; Reddy, R. R.; Reddy, D. M.; Reddy, K. S. C. Polymorphs of Lopinavir. U.S. Patent8\u202f445\u202f506\u202fB2. Published May 21, 2013.","DOI":"10.4103\/2277-8632.117191"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAM.0000016282.77887.1f"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(96)00494-2"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2013.09.010"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24492"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2019.100035"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12217"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2010.10.002"},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.0c00131"},{"key":"ref33\/cit33","doi-asserted-by":"publisher","DOI":"10.1021\/mp034006h"},{"key":"ref34\/cit34","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23698"},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31803133c5"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2932"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.3c00072","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.3c00072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T08:28:19Z","timestamp":1680510499000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.3c00072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"alternative-id":["10.1021\/acs.molpharmaceut.3c00072"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00072","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]}}}